PRVL  Prevail Therapeutics Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies. The company was founded in 2017 and is based in New York, New York.